Neoplasms, Unknown Primary: all 107 studies

Page 1 of 2. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.

• A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)RecruitingNCT07761429Phase 2/3
• Living Without Answers - ILLUMINATE CUPNot yet recruitingNCT07712965
• Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)RecruitingNCT07524114
• 18F-FAPI PET in Cancers of Unknown Primary SiteNot yet recruitingNCT07372963
• The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)Not yet recruitingNCT07366008Not applicable
• Enabling Genomic Testing in Cancer of Unknown PrimaryRecruitingNCT06695494
• [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary OriginRecruitingNCT06644716Not applicable
• PaCIFiC-CUP Classifies Cancer of Unknown PrimaryRecruitingNCT06140992
• Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and NeckRecruitingNCT06100081Not applicable
• A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)RecruitingNCT05576974Phase 2
• FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown PrimaryRecruitingNCT05263700Not applicable
• Solving Riddles Through SequencingRecruitingNCT05046444
• TCF-001 TRACK (Target Rare Cancer Knowledge) StudyRecruitingNCT04504604Not applicable
• Cancer Genetic Testing in Ethnic PopulationsRecruitingNCT04475640Not applicable
• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 2
• Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck CancerRecruitingNCT03010150
• Ontario-wide Cancer TArgeted Nucleic Acid EvaluationRecruitingNCT02906943
• Integrated Cancer Repository for Cancer ResearchRecruitingNCT02012699
• Sintilimab in Cancer of Unknown PrimaryCompletedNCT05024968Phase 2Results posted
• Trial of Pembrolizumab in Cancer of Unknown PrimaryCompletedNCT03752333Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)CompletedNCT03391973Phase 2Results posted
• Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are MetastaticActive, not recruitingNCT02721732Phase 2Results posted
• PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT01816984Phase 1/2Results posted
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyCompletedNCT01806675Phase 1/2Results posted
• A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation TherapyCompletedNCT01624220Not applicableResults posted
• Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckCompletedNCT01044433Phase 2Results posted
• Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown PrimaryCompletedNCT00936702Phase 2Results posted
• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown PrimaryCompletedNCT00873119Phase 2Results posted
• Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00513435Phase 2Results posted
• Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00507767Phase 2Results posted
• Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00387335Phase 2Results posted
• Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary SiteCompletedNCT00360360Phase 2Results posted
• Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown PrimaryTerminatedNCT00201734Phase 1/2Results posted
• Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary SiteCompletedNCT00193609Phase 2Results posted
• Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary SiteCompletedNCT00193596Phase 3Results posted
• SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00095628Phase 2Results posted
• Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown PrimaryCompletedNCT00066781Phase 2Results posted
• Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown PrimaryCompletedNCT05841966Not applicable
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
• Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown PrimaryStatus unknownNCT05241132Phase 2
• Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in ChinaStatus unknownNCT04952103
• Carcinoma of Unknown Primary (CUP): a Comparison Across Tissue and Liquid BiomarkersCompletedNCT04750109
• Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsActive, not recruitingNCT04584008Not applicable
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersActive, not recruitingNCT04459273Phase 1
• Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit StudyCompletedNCT04456140Phase 1
• Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.WithdrawnNCT04276597Phase 2
• Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSASCompletedNCT04189107Phase 3
• Nivolumab/Ipilimumab in Second Line CUP-syndromeStatus unknownNCT04131621Phase 2
• Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
• Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUPStatus unknownNCT04025970
• The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Status unknownNCT03896958
• A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.TerminatedNCT03628079Phase 1/2
• HARE-40: HPV Anti-CD40 RNA vaccinECompletedNCT03418480Phase 1/2
• Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown PrimaryCompletedNCT03278600Phase 3
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid TumorsCompletedNCT03053466Phase 1
• Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying LesionsStatus unknownNCT02789371Not applicable
• Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordActive, not recruitingNCT02713269Phase 2
• Outcomes of FoundationOne Directed Therapy in Cancer of Unknown PrimaryCompletedNCT02628379
• A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)CompletedNCT02607202Phase 2
• Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown PrimaryStatus unknownNCT02590055Phase 2
• Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying LesionStatus unknownNCT02327065Not applicable
• Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerCompletedNCT02245100
• Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02035527Phase 1
• Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineCompletedNCT01845337Phase 2
• Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal MalignanciesCompletedNCT01643499Phase 1
• Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUPCompletedNCT01540058Phase 3
• Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerTerminatedNCT01528137Phase 1
• Integrated Molecular Profiling in Advanced Cancers TrialActive, not recruitingNCT01505400
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and NeckCompletedNCT01334177Phase 1
• Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell CancerCompletedNCT01316757Phase 2
• Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)CompletedNCT01202786
• Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTerminatedNCT00906360Phase 1
• Paclitaxel/Carboplatin With or Without Cetuximab in CUPStatus unknownNCT00894569Phase 2
• Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary CancerCompletedNCT00876408
• Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
• Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary TumorWithdrawnNCT00458315Phase 2
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation TherapyCompletedNCT00388024
• Gemcitabine in Treating Patients With Metastatic Cancer of Unknown PrimaryCompletedNCT00357630Phase 2
• Gemox as First and Second Line Therapy in Unknown Primary CancerCompletedNCT00353145Phase 2
• Positron Emission Tomography - Computed Tomography (PET-CT) Scan as a Diagnostic Method in Unknown Primary TumorsCompletedNCT00269373
• Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary SiteCompletedNCT00193622Phase 2
• Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary SiteTerminatedNCT00148135Phase 2
• Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary OriginWithdrawnNCT00119314Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00098631Phase 2
• S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00096512Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00049283Phase 1
• Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary TumorCompletedNCT00047125Phase 3
• Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and NeckCompletedNCT00033618Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of OriginStatus unknownNCT00022178Phase 3
• SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCompletedNCT00006361Phase 2

← Neoplasms, Unknown Primary overview